This is a routine public relations filing with no new financial or clinical data. Traders should monitor upcoming trial results or regulatory developments for material updates. The stock's micro-cap size ($1M market cap) may lead to volatility on sentiment-driven news despite limited substance.
Price Chart
Executive Summary
Clearmind Medicine issued a press release via Form 6-K welcoming President Trump's April 18, 2026, executive order to accelerate FDA review of psychedelic therapies and expand patient access, particularly for veterans. The company highlighted that its compound MEAI was referenced in recent bipartisan legislation (H.R. 7091) and that it is advancing Phase I/IIa trials for CMND-100 in alcohol use disorder at Yale and Johns Hopkins.
Key Facts
- Clearmind Medicine issued a press release supporting President Trump's executive order to accelerate FDA review of psychedelic therapies.
- The executive order supports breakthrough therapy designation and expanded access for psychedelic drugs, particularly for veterans with PTSD, depression, and alcohol use disorder.
- Clearmind's compound MEAI was named in H.R. 7091, proposed legislation to expand veteran access to emerging treatments.
- The company is conducting FDA-approved Phase I/IIa trials of CMND-100 for alcohol use disorder at Yale and Johns Hopkins.
- No financial data, clinical results, or material operational changes were disclosed in the filing.
Financial Impact
No direct financial impact disclosed
Risk Factors
- High stock volatility due to micro-cap status and speculative nature of psychedelic biotech sector
- No guarantee that the executive order or proposed legislation will lead to accelerated approvals or funding
- Clinical trial timelines and outcomes remain uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-045585 |
| Document: ea028696902ex99-1_clearmind.htm | 0001213900-26-045585 |
| Document: 0001213900-26-045585-index-headers.html | 0001213900-26-045585 |
| Document: 0001213900-26-045585-index.html | 0001213900-26-045585 |
| Document: 0001213900-26-045585.txt | 0001213900-26-045585 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $5.97 (+0.80%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $5.97 (−8.20%) |
Oct 16, 2026 11d ago | 6-K | $6.00 | awaiting T+60 | — | $5.97 (+0.55%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $5.97 (−4.22%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.97 (+602.04%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.97 (+602.04%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.97 (−13.06%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.97 (+532.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers